AstronauTx has received funding from The Michael J Fox Foundation for Parkinson’s Research (MJFF), while Parkinson’s UK is funding an additional complementary research effort in collaboration with University College London (UCL). The MJFF-funded project, titled ‘Ligand-Gated Ion Channel Modulation as a Disease-Modifying Treatment for Prodromal Synucleinopathies’, will… Read More
AstronauTx has secured the exclusive worldwide rights to research, develop, manufacture and commercialise therapeutic candidates arising from its collaboration with biopharma company Saniona. Saniona and AstronauTx entered into a research collaboration and option agreement in 2023 to discover new treatments for neurological conditions by modulating a novel,… Read More
University College London (UCL) spinout AstronauTx has closed a £48m ($61m) Series A financing to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. The company was launched in 2019, initially to build on research from the Alzheimer’s Research UK UCL Drug Discovery Institute (UCL… Read More
